Polymyositis Overview
Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. Polymyositis (PM), an autoimmune disorder, develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1 causing damage to the endomysium of skeletal muscles. Polymyositis develops gradually over time, and it rarely affects persons younger than age 18. The Polymyositis diagnosis is often suspected in people with proximal muscle weakness and other signs and symptoms associated with the disease.
“Polymyositis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polymyositis Market.
The Polymyositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Polymyositis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Polymyositis treatment therapies with a considerable amount of success over the years. Polymyositis Key players such as - Viela Bio, ImmunoForge K, Kezar Life Sciences, Inc., BristolMyers Squibb, Janssen Pharmaceutical, and others, are developing therapies for the Polymyositis treatment
- Polymyositis Emerging therapies such as - VIB7734, PF1801, KZR-616, Abatacept, Ustekinumab, and others are expected to have a significant impact on the Polymyositis market in the coming years
- In January 2020, kezar Life Sciences initiated a Phase II randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD)of treatment with KZR-616 in patients with active Polymyositis (PM) or Dermatomyositis (DM)
- In October 2020, the US Food and Drug Administration (FDA) has granted Orphan Drug Designations (ODD) for KZR-616for the treatment of polymyositis (PM) and dermatomyositis (DM)
- In November 2020, Kezar Life Sciences initiated an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active PM or DM who completed the double-blind treatment period of Study KZR-616-003
Polymyositis Pipeline Therapeutics Assessment
- Polymyositis Assessment by Product Type
- Polymyositis By Stage and Product Type
- Polymyositis Assessment by Route of Administration
- Polymyositis By Stage and Route of Administration
- Polymyositis Assessment by Molecule Type
- Polymyositis by Stage and Molecule Type
DelveInsight's Polymyositis Report covers around 7+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Emerging Polymyositis Drugs Under Different Phases of Clinical Development Include:
- Research programme: polymyositis: CytoDyn
- VIB7734: Viela Bio
- PF1801: ImmunoForge K
- KZR-616: Kezar Life Sciences, Inc
- Abatacept: BristolMyers Squibb
- Ustekinumab: Janssen Pharmaceutical
Get a Free Sample PDF Report to know more about Polymyositis Pipeline Assessment
Polymyositis Pipeline Analysis:
The Polymyositis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the Polymyositis treatment with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polymyositis Treatment.
- Polymyositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Polymyositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polymyositis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Polymyositis product details are provided in the report. Download the Polymyositis pipeline report to learn more about the emerging Polymyositis therapies
Polymyositis Pipeline Market Drivers
- Growing cases of chronic muscle inflammation
- Continuous advancement in technology
- Increased injuries of muscle
Polymyositis Pipeline Market Barriers
- High cost of drugs
- Lack of approved therapies
Scope of Polymyositis Pipeline Drug Insight
- Coverage: Global
- Key Polymyositis Companies: Viela Bio, ImmunoForge K, Kezar Life Sciences, Inc., BristolMyers Squibb, Janssen Pharmaceutical, and others
- Key Polymyositis Therapies: VIB7734, PF1801, KZR-616, Abatacept, Ustekinumab, and others
- Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies
- Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers
Request for Sample PDF Report for Polymyositis Pipeline Assessment and clinical trials
Table of Contents
| 1 | Polymyositis Report Introduction |
| 2 | Polymyositis Executive Summary |
| 3 | Polymyositis Overview |
| 4 | Polymyositis- Analytical Perspective In-depth Commercial Assessment |
| 5 | Polymyositis Pipeline Therapeutics |
| 6 | Polymyositis Late Stage Products (Phase II/III) |
| 7 | Polymyositis Mid Stage Products (Phase II) |
| 8 | Polymyositis Early Stage Products (Phase I) |
| 9 | Polymyositis Preclinical Stage Products |
| 10 | Polymyositis Therapeutics Assessment |
| 11 | Polymyositis Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Polymyositis Key Companies |
| 14 | Polymyositis Key Products |
| 15 | Polymyositis Unmet Needs |
| 16 | Polymyositis Market Drivers and Barriers |
| 17 | Polymyositis Future Perspectives and Conclusion |
| 18 | Polymyositis Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
Download Sample PDF Report to know more about Polymyositis drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
